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207* Recovery of lung function after intensive treatment due to
pulmonary exacerbation in children with cystic ﬁbrosis
R. Kraemer1, S. Gallati2, M.H. Schoeni1. 1University of Berne, Department
of Paediatrics, Berne, Switzerland; 2University of Berne, Division of Human
Genetics, Berne, Switzerland
Rationale: It is generally believed that lung function recovers after treatment of
pulmonary exacerbations in CF, although it is unclear how often return to previous
baseline is achieved.
Objectives: (1) Determination of the proportion of children who signiﬁcantly
improved or failed to recover lung function, and (2) identiﬁcation of factors
associated with success or failure.
Methods: Data from 24 CF-patients (15 males, 9 females) collected prior and
after intensive treatment of pulmonary exacerbations, hospitalized on 44 occasions
were investigated. Serial measurements pertaining to functional residual capac-
ity (FRCpleth, FRCMBNW), lung clearance index (LCI), volume of trapped gas
(VTG), effective speciﬁc airway resistance (sReff ), forced expiratory indices (FEV1,
FEF50), PaO2 and PaCO2.
Results: Signiﬁcant changes were observed for oxygenation given by PaO2
(p< 0.001), as well as sReff (p = 0.032) and FEF50 (p = 0.038) indicating an
improvement of lung function, however, only after 24 occasions (54.5%). After
13 occasions (29.5%) lung function remained within a ±8% change, and After
7 occasions (15.9%) lung function even deteriorated.
Conclusions: Improvement of oxygenation depended speciﬁcally on improvement
of obstruction (sReff ) and small airway function (FEF50). In contrast, deterioration
of gas exchange was closely associated with failure to recover ventilation inhomo-
geneities (LCI) and/or for the decrease of trapped gas (VTG). In consequence, these
complex physiopathological interactions regarding assessment of treatment efﬁcacy
demonstrate, that outcome parameters have to be carefully selected and deﬁned,
and not restricted to spirometric parameters only.
208* Long-term non-invasive ventilation in adults with cystic ﬁbrosis:
experience over two decades
W.G. Flight1, J. Shaw1, S. Johnson1, K. Webb1, A. Jones1, A.M. Bentley2,
R. Bright-Thomas1. 1University Hospital of South Manchester, Manchester Adult
Cystic Fibrosis Centre, Manchester, United Kingdom; 2University Hospital of
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Objectives: Non-invasive ventilation (NIV) is accepted as a bridge to lung trans-
plantation in CF but its role beyond this is unclear. We aimed to determine the
effect of long-term NIV on lung function and survival in advanced CF.
Methods:We reviewed the records of all CF patients commenced on long-term NIV
at the Manchester Adult CF Centre before October 2010. Weight, lung function and
antibiotic therapy were recorded for the 3 years before and after initiation of NIV.
Results: 48 patients have received long-term NIV since 1991 and data were
available for 47 of these. Median age at NIV set-up was 29 years (range 16−47).
Mean±SD FEV1%-predicted was 20.7±6.0%. 17 patients (36.2%) underwent
lung transplantation, 13 (27.6%) died without transplantation, 3 (6.4%) had NIV
withdrawn and 14 (29.8%) remain on NIV. Median time from NIV set-up to death
or transplantation was 27 (3−90) and 16 (2−44) months respectively. Those still
alive have been on NIV for a median of 14.5 (3−89) months. Mean IPAP & EPAP
at set-up were 22.5 and 2.7cmH2O.
FEV1 and FVC fell by a mean of 398 and 685ml over the 3 years before initiation
of NIV but increased by 43 and 142ml in the 3 years after NIV set-up. The
improvements in FEV1 and FVC at both 1 and 3 years post-NIV were statistically
signiﬁcant compared to equivalent periods before NIV (p< 0.01). There was no
signiﬁcant difference in IV antibiotic usage over the 12 months before and after
NIV (median 65 v 86 days/yr; p = 0.102).
Conclusions: NIV appears to halt the decline in lung function in patients with
advanced CF and improvements are maintained at three years of follow-up. This
data supports the use of long-term NIV in advanced CF.
209 Inhaled hypertonic saline in infants with cystic ﬁbrosis from
Argentina
V. D’Alessandro1, G. de la Fuente1, G. Diez1, E. Segal1. 1Children’s Hospital,
Pulmonary, La Plata, Argentina
Introduction: Inhaled hypertonic saline (HS) using concentrations ranging from
3% to 7% has been used for sputum induction and positively affects lung function
in children with cystic ﬁbrosis (CF). However, safety and tolerability of HS in
infants have been established in few studies.
Objective: To assess safety and tolerability of the inhalation of a single dose of
7% HS in infants with CF undergoing routine infant pulmonary function testing.
Material and Methids: Cross sectional study. We measured: Maximal Expiratory
Flow at FRC (V′maxFRC) using rapid thoracic compression with Jaeger® equip-
ment. The measurement was performed before and after the inhalation of 4ml of
7% HS administered via face mask. Previous HS infants received four puffs of a
short-acting bronchodilator. Infants had to be stable and free of acute respiratory
infections. Oxygen saturation, respiratory rate, heart rate, cough, and wheezing were
recorded throughout the study. T-test was performed to compare the means of the
indicators.
Results: We evaluated 10 patients with a mean age of 18 months. Seven completed
the entire study including HS lung function measurement. Mean value of V′maxFRC
did not exhibit a signiﬁcant reduction from baseline to after HS inhalation values.
Oxygen saturation, respiratory rate, heart rate did not change in any of the subjects
during or after HS inhalation.
Conclusions: Results suggest that inhalation of a single dose HS is safe in infants
with CF who are free of respiratory exacerbation and had pre-administration of
a short bronchodilator prior saline inhalation. A longitudinal long term follow-up
would also be helpful in order to evaluate the beneﬁts of the treatment.
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U. Graepler-Mainka1, V. Icheva1, G. Herrmann1, C. Adams1, M. Stern1,
B. Zonnenberg2, J. Riethmu¨ller3. 1University Children’s Hospital Tu¨bingen, I,
Tu¨bingen, Germany; 2Bartzon BV, Nieuwegein, Netherlands; 3University Children’s
Hospital, Dept 2, Tuebingen, Germany
Introduction: Inhaled hypertonic saline is standard care in CF-patients. Two work
groups in Finland and Russia reported data about the halotherapy which applies
dry powder saline in air in a special setting for patients with chronic lung disease.
They found an increase in lung function parameters and a reduction of pulmonary
exacerbations. In a small pilot study, halotherapy was proven for safety and efﬁcacy
in 6 CF-patients.
Methods: Dry powder aerosol was insufﬂated in a dry and well-tempered room with
salt concentrations of 10mg/m3 in the air. Halotherapy was proven for 45 minutes
on ﬁve consecutive days in a wellness area. Sputum was sampled, leukocytes
and bacteria and lung function parameters (FEV1, MMEF) were analysed during,
and one hour after, therapy. Secondary aims were side effects. No prophylactic
antiobstructive therapy was implicated.
Results: We found in six adult CF-patients (i) a signiﬁcantly increased secretolysis
(mean amount of sputum 7.1±4.4g; p = 0.008) within and one hour after dry
powder aerosol inhalation, (ii) a signiﬁcant increase in leucocytes (mean 39±78/ml;
p = 0.049) and P. aeruginosa colony counts (mean 0.3±0.5log; p = 0.017) in expec-
torated sputa and (iii) a signiﬁcant improvement in lung function parameters, FEV1
(mean 3.8±2.5%; p = 0.019) and MMEF (mean 6.6±6%; p = 0.05) after 5 days of
therapy.
Conclusion: These data conﬁrm the ﬁndings of the trials carried out in Finland
and Russia in patients with chronic lung diseases. We found a well-tolerated dry
powder inhalation with an increased sputum production and similar clinical effects
to saline inhalation in CF-patients, which must be consolidated by a larger clinical
trial.
